Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 359 articles:
HTML format



Single Articles


    July 2021
  1. VARETTONI M, Orlandi E, Zibellini S, Rossi M, et al
    Prognostic impact of somatic mutations on time to first treatment: results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
    Am J Hematol. 2021 Jul 30. doi: 10.1002/ajh.26302.
    PubMed    


  2. KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
    Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
    Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.
    PubMed    


  3. BROCCOLI A, Argnani L, Nanni L, Terragna C, et al
    The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a thirty-year experience.
    Am J Hematol. 2021 Jul 10. doi: 10.1002/ajh.26287.
    PubMed     Abstract available


  4. GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
    Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Am J Hematol. 2021;96:781-789.
    PubMed     Abstract available


  5. HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
    Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
    Am J Hematol. 2021;96:E259-E262.
    PubMed    


  6. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:E237-E239.
    PubMed    


  7. JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
    A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
    Am J Hematol. 2021;96:E226-E229.
    PubMed    


  8. OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
    Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
    Am J Hematol. 2021;96:E223-E225.
    PubMed    


    June 2021
  9. JABBOUR E, Patel K, Jain N, Duose D, et al
    Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
    Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
    PubMed     Abstract available


  10. LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
    Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
    PubMed    


  11. MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
    Ruxolitinib for refractory large granular lymphocyte leukemia.
    Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.
    PubMed    


  12. HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
    Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
    Am J Hematol. 2021;96:E187-E189.
    PubMed    


    May 2021
  13. AL-SAWAF O, Gentile B, Devine J, Zhang C, et al
    Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26260.
    PubMed     Abstract available


  14. PICIOCCHI A, Messina M, Elia L, Vitale A, et al
    Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.
    Am J Hematol. 2021 May 28. doi: 10.1002/ajh.26253.
    PubMed    


  15. ST MARTIN EC, Ferrer A, Wudhikarn K, Mangaonkar A, et al
    Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes.
    Am J Hematol. 2021 May 24. doi: 10.1002/ajh.26250.
    PubMed    


  16. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
    PubMed    


  17. JAIN N, Maiti A, Ravandi F, Konopleva M, et al
    Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia.
    Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.
    PubMed     Abstract available


  18. MORABITO F, Del Poeta G, Mauro FR, Reda G, et al
    TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
    Am J Hematol. 2021 May 14. doi: 10.1002/ajh.26235.
    PubMed    


  19. HALL KH, Brooks A, Waller EK
    Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26231.
    PubMed    


  20. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Am J Hematol. 2021;96:E168-E171.
    PubMed    


  21. OTHMAN TA, Mei M, Zhang J, Aldoss I, et al
    Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Am J Hematol. 2021;96:E140-E143.
    PubMed    


    April 2021
  22. KADIA TM, Ravandi F, Borthakur G, Konopleva M, et al
    Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2021 Apr 26. doi: 10.1002/ajh.26206.
    PubMed     Abstract available


  23. YILMAZ M, Daver N, Borthakur G, Kadia T, et al
    FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
    Am J Hematol. 2021 Apr 23. doi: 10.1002/ajh.26202.
    PubMed    


  24. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
    Am J Hematol. 2021 Apr 20. doi: 10.1002/ajh.26201.
    PubMed    


  25. JAMY O, Godby R, Sarmad R, Costa LJ, et al
    Survival of Chronic Myeloid Leukemia Patients in Comparison to the General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26195.
    PubMed    


  26. PELLAND-MARCOTTE MC, Kulkarni K, Athale UH, Pole JD, et al
    Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C.
    Am J Hematol. 2021 Apr 13. doi: 10.1002/ajh.26193.
    PubMed     Abstract available


  27. APEL A, Moshe Y, Ofran Y, Gural A, et al
    Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice.
    Am J Hematol. 2021 Apr 9. doi: 10.1002/ajh.26190.
    PubMed     Abstract available


  28. DONG N, Castillo Tokumori F, Isenalumhe L, Zhang Y, et al
    Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases.
    Am J Hematol. 2021 Apr 5. doi: 10.1002/ajh.26183.
    PubMed     Abstract available


  29. GANGAT N, Szuber N, Jawaid T, Hanson CA, et al
    Young platelet millionaires with essential thrombocythemia.
    Am J Hematol. 2021;96:E93-E95.
    PubMed    


  30. PARDANANI A
    Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:508-525.
    PubMed     Abstract available


    March 2021
  31. SHORT NJ, Konopleva M, Kadia T, Kebriaei P, et al
    An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Am J Hematol. 2021 Mar 29. doi: 10.1002/ajh.26175.
    PubMed    


  32. AUDIL HY, Hampel PJ, Van Dyke DL, Achenbach SJ, et al
    The Prognostic Significance of del6q23 in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2021 Mar 22. doi: 10.1002/ajh.26168.
    PubMed    


  33. LIU S, Deng B, Yin Z, Lin Y, et al
    Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Am J Hematol. 2021 Mar 16. doi: 10.1002/ajh.26160.
    PubMed     Abstract available


  34. SALHOTRA A, Aribi A, Ngo D, Zhang J, et al
    Outcome of secondary Acute Myeloid Leukemia treated with Hypomethylating agent plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin-Cytarabine (CPX-351).
    Am J Hematol. 2021 Mar 14. doi: 10.1002/ajh.26157.
    PubMed    


  35. SASAKI K, Jabbour E, Short NJ, Jain N, et al
    Acute Lymphoblastic Leukemia: A Population- based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results (SEER) Database, 1980-2017.
    Am J Hematol. 2021 Mar 11. doi: 10.1002/ajh.26156.
    PubMed     Abstract available


  36. BALL BJ, Hsu M, Devlin SM, Arcila M, et al
    The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
    Am J Hematol. 2021 Mar 1. doi: 10.1002/ajh.26146.
    PubMed    


  37. WILHELMSSON M, Jahnukainen K, Winiarski J, Abrahamsson J, et al
    Hospitalizations in long-term survivors of childhood AML treated with allogeneic HCT-An Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.
    Am J Hematol. 2021;96:E74-E77.
    PubMed    


  38. FERNANDES F, Ramalho R, Barreira R, Silveira M, et al
    Large granular lymphocytosis induced by dasatinib.
    Am J Hematol. 2021;96:395-396.
    PubMed    


    February 2021
  39. CHATZIDIMITRIOU C, Pappa V, Lakiotaki E, Plata E, et al
    Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
    Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26145.
    PubMed    


  40. MORITA K, Jain N, Kantarjian H, Takahashi K, et al
    Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine.
    Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26144.
    PubMed     Abstract available


  41. MOU T, Pawitan Y, Stahl M, Vesterlund M, et al
    The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia.
    Am J Hematol. 2021 Feb 24. doi: 10.1002/ajh.26141.
    PubMed     Abstract available


  42. FATHI AT, Stein EM, DiNardo CD, Levis MJ, et al
    Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.
    Am J Hematol. 2021 Feb 24. doi: 10.1002/ajh.26142.
    PubMed     Abstract available


  43. DAVER N, Salhotra A, Brandwein JM, Podoltsev NA, et al
    A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.
    Am J Hematol. 2021 Feb 22. doi: 10.1002/ajh.26136.
    PubMed    


  44. VENUGOPAL S, Maiti A, DiNardo CD, Loghavi S, et al
    Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26122.
    PubMed    


  45. WANG S, Wang X, Ye C, Cheng H, et al
    Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26123.
    PubMed    


  46. BEGNA KH, Gangat N, Al-Kali A, Litzow MR, et al
    Acute myeloid leukemia after age 70 years: a retrospective comparison of survival following treatment with intensive vs HMA +/- venetoclax chemotherapy.
    Am J Hematol. 2021 Feb 2. doi: 10.1002/ajh.26112.
    PubMed    


  47. ZHENG H, Mineishi S, Claxton D, Zhu J, et al
    A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.
    Am J Hematol. 2021;96:E46-E50.
    PubMed    


    January 2021
  48. RICHARDSON DR, Swoboda DM, Moore DT, Johnson SM, et al
    Genomic Characteristics and Prognostic Significance of Co-mutated ASXL1/SRSF2 Acute Myeloid Leukemia.
    Am J Hematol. 2021 Jan 27. doi: 10.1002/ajh.26110.
    PubMed     Abstract available


  49. HERGOTT CB, Dal Cin P, Hornick JL, Winer ES, et al
    Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion.
    Am J Hematol. 2021 Jan 25. doi: 10.1002/ajh.26107.
    PubMed    


  50. JONAS BA, Fisch SC, Rosenberg AS, Hoeg RT, et al
    Phase I Study of Escalating Doses of Carfilzomib with HyperCVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
    Am J Hematol. 2021 Jan 21. doi: 10.1002/ajh.26105.
    PubMed    


    December 2020
  51. BROWN JR, Walker SR, Heppler LN, Tyekucheva S, et al
    Targeting Constitutively Active STAT3 in Chronic Lymphocytic Leukemia: A Clinical Trial of the STAT3 Inhibitor Pyrimethamine with Pharmacodynamic Analyses.
    Am J Hematol. 2020 Dec 29. doi: 10.1002/ajh.26084.
    PubMed    


  52. CORTES JE, Mehta P
    Determination of Fitness and Therapeutic Options in Older Patients With Acute Myeloid Leukemia.
    Am J Hematol. 2020 Dec 23. doi: 10.1002/ajh.26079.
    PubMed     Abstract available


  53. WANG HP, Zhou YL, Huang X, Zhang Y, et al
    CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.
    Am J Hematol. 2020 Dec 11. doi: 10.1002/ajh.26069.
    PubMed     Abstract available


  54. TESTI AM, Canichella M, Vitale A, Piciocchi A, et al
    Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase ii pediatric-like gimema lal-1308 trial.
    Am J Hematol. 2020 Dec 7. doi: 10.1002/ajh.26066.
    PubMed     Abstract available


  55. KOLLER PB, Zhang H, Kantarjian H, Jabbour E, et al
    GATA3 rs3824662A allele is associated with CRLF2 rearranged B-cell acute lymphoblastic leukemia in adults and adolescents and young adults (AYAs) and is associated with poor prognosis.
    Am J Hematol. 2020 Dec 4. doi: 10.1002/ajh.26065.
    PubMed    


  56. MAITI A, Qiao W, Sasaki K, Ravandi F, et al
    Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality.
    Am J Hematol. 2020 Dec 2. doi: 10.1002/ajh.26061.
    PubMed     Abstract available


  57. DIAO S, Nichols ED, DiNardo C, Konopleva M, et al
    Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax.
    Am J Hematol. 2020 Dec 1. doi: 10.1002/ajh.26060.
    PubMed    


  58. PATEL S, Nayernama A, Jones SC, de Claro RA, et al
    BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
    Am J Hematol. 2020;95:E332-E335.
    PubMed    


  59. SASAKI K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, et al
    Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
    Am J Hematol. 2020;95:E326-E329.
    PubMed    


  60. OFORI K, Soderquist CR, Murty VV, Park D, et al
    The clinical and pathological features of plasma cell myeloma post solid organ transplantation.
    Am J Hematol. 2020;95:1531-1541.
    PubMed     Abstract available


    November 2020
  61. ARSLAN S, Zhang J, Dhakal P, Moran J, et al
    Outcomes of Therapy with Venetoclax Combined with A Hypomethylating Agent in Favorable-Risk Acute Myeloid Leukemia.
    Am J Hematol. 2020 Nov 23. doi: 10.1002/ajh.26057.
    PubMed    


  62. SASAKI K, Jabbour EJ, Ravandi F, Konopleva M, et al
    The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes.
    Am J Hematol. 2020 Nov 12. doi: 10.1002/ajh.26047.
    PubMed     Abstract available


  63. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, et al
    Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2020 Nov 6. doi: 10.1002/ajh.26044.
    PubMed    


  64. GARCIA-MANERO G, Chien KS, Montalban-Bravo G
    Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Am J Hematol. 2020;95:1399-1420.
    PubMed     Abstract available


  65. MANNELLI F, Gianfaldoni G, Bencini S, Piccini M, et al
    Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.
    Am J Hematol. 2020;95:1304-1313.
    PubMed     Abstract available


    October 2020
  66. POLLYEA DA, Pratz K, Letai A, Jonas BA, et al
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study.
    Am J Hematol. 2020 Oct 29. doi: 10.1002/ajh.26039.
    PubMed     Abstract available


  67. BRANDWEIN JM, Hallett D, Karkhaneh M, Zhu N, et al
    An Evaluation of No-Treatment Decisions in Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2020 Oct 6. doi: 10.1002/ajh.26012.
    PubMed    


  68. RAUTENBERG C, Germing U, Stepanow S, Lauseker M, et al
    Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia.
    Am J Hematol. 2020 Oct 5. doi: 10.1002/ajh.26013.
    PubMed    



  69. Abstracts from the 2020 Lymphoma, Leukemia and Myeloma Congress October 21-24, 2020.
    Am J Hematol. 2020;95 Suppl 1:S3-S38.
    PubMed    


    September 2020
  70. POIANI M, Labopin M, Battipaglia G, Beelen DW, et al
    The impact of cytogenetic risk on the outcomes of Allogeneic Hematopoietic Cell Transplantation in patients with relapsed/refractory acute myeloid leukemia: on behalf of the Acute Leukemia Working Party (ALWP) of the EBMT.
    Am J Hematol. 2020 Sep 17. doi: 10.1002/ajh.26000.
    PubMed     Abstract available


  71. MARZOLLO A, Maestrini G, La Starza R, Elia L, et al
    A novel germline variant in PIK3R1 results in SHORT syndrome associated with TAL/LMO T-cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2020 Sep 16. doi: 10.1002/ajh.25998.
    PubMed    


  72. CHO BS, Min GJ, Park S, Park SS, et al
    Haploidentical versus matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study.
    Am J Hematol. 2020 Sep 9. doi: 10.1002/ajh.25993.
    PubMed     Abstract available


  73. BARON F, Labopin M, Ruggeri A, Sierra J, et al
    Impact of detectable measurable residual disease on umbilical cord blood transplantation.
    Am J Hematol. 2020;95:1057-1065.
    PubMed     Abstract available


  74. SMITH CJ, Kluck LA, Ruan GJ, Ashrani AA, et al
    The differential diagnosis of basophilia in patients undergoing BCR-ABL testing.
    Am J Hematol. 2020;95:E216-E217.
    PubMed    


  75. MARGOLSKEE E, Pillai V
    Loss of surface CD3 expression in allogeneic CAR T-cells.
    Am J Hematol. 2020;95:1115-1116.
    PubMed    


    August 2020
  76. PAGNANO KBB, Lopes ABP, Miranda EC, Delamain MT, et al
    Efficacy and Safety of Pioglitazone in a Phase 1/2 Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia with Deep Molecular Response.
    Am J Hematol. 2020 Aug 30. doi: 10.1002/ajh.25986.
    PubMed    


  77. VAN ELSSEN CHMJ, Ciurea SO
    NK Cell Alloreactivity in Acute Myeloid Leukemia in the Post-transplant Cyclophosphamide Era.
    Am J Hematol. 2020 Aug 28. doi: 10.1002/ajh.25983.
    PubMed     Abstract available


  78. MORSIA E, McCullough K, Joshi M, Cook J, et al
    Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25978.
    PubMed     Abstract available


  79. ESTEY EH
    Acute myeloid leukemia: 2021 update on risk-stratification and management.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25975.
    PubMed    


  80. SANDBERG Y, Verhoeven GT, Weerkamp F, Broyl A, et al
    Primary plasma cell leukemia mimicking a Pancoast tumor.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25977.
    PubMed    


  81. PLEYER C, Tian X, Rampertaap S, Mu R, et al
    A Phase II Study of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia.
    Am J Hematol. 2020 Aug 18. doi: 10.1002/ajh.25968.
    PubMed    


  82. CANDONI A, Lazzarotto D, Ferrara F, Curti A, et al
    Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma. the campus-all study.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25957.
    PubMed     Abstract available


  83. SAYGIN C, Larkin K, Blachly JS, Orwick S, et al
    A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25958.
    PubMed     Abstract available


  84. JONDREVILLE L, Krzisch D, Chapiro E, Nguyen-Khac F, et al
    The complex karyotype and chronic lymphocytic leukemia. A review of the literature.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25956.
    PubMed     Abstract available


  85. JENG MY, Dutta R, Tan IT, Zhang TY, et al
    Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies.
    Am J Hematol. 2020 Aug 3. doi: 10.1002/ajh.25949.
    PubMed    


  86. KOFFMAN B, Mato A, Byrd JC, Danilov A, et al
    Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts.
    Am J Hematol. 2020;95:E199-E203.
    PubMed    


  87. PATNAIK MM, Lasho T, Padron E, McCullough K, et al
    Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic.
    Am J Hematol. 2020;95:E203-E208.
    PubMed    


    July 2020
  88. BORTHAKUR G, Zeng Z, Cortes JE, Chen HC, et al
    Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
    Am J Hematol. 2020 Jul 22. doi: 10.1002/ajh.25943.
    PubMed     Abstract available


  89. ABAZA Y, Kantarjian H, Alwash Y, Borthakur G, et al
    Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia.
    Am J Hematol. 2020 Jul 18. doi: 10.1002/ajh.25939.
    PubMed     Abstract available


  90. DHOLARIA B, Labopin M, Angelucci E, Ciceri F, et al
    Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia.
    Am J Hematol. 2020 Jul 13. doi: 10.1002/ajh.25934.
    PubMed     Abstract available


  91. ALDOSS I, Zhang J, Mei M, Al Malki MM, et al
    Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
    Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25929.
    PubMed     Abstract available


  92. COLADO A, Marin Franco JL, Elias EE, Amondarain M, et al
    Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils.
    Am J Hematol. 2020;95:E174-E178.
    PubMed    


  93. KIM GYG, Burns J, Freyer CW, Hamilton KW, et al
    Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
    Am J Hematol. 2020;95:792-798.
    PubMed     Abstract available


    June 2020
  94. BOCK AM, Pollyea DA
    Venetoclax with Azacitidine for Two Younger Jehovah's Witness Patients with High Risk Acute Myeloid Leukemia.
    Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25916.
    PubMed    


  95. DAGA S, Rosenberger A, Kashofer K, Heitzer E, et al
    Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
    Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25918.
    PubMed     Abstract available


  96. OHANIAN M, Kantarjian HM, Shoukier M, Dellasala S, et al
    The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia.
    Am J Hematol. 2020 Jun 17. doi: 10.1002/ajh.25907.
    PubMed     Abstract available


  97. IURLO A, Cattaneo D, Malato A, Accurso V, et al
    Low-Dose Ponatinib Is A Good Option In Chronic Myeloid Leukemia Patients Intolerant To Previous Tkis.
    Am J Hematol. 2020 Jun 17. doi: 10.1002/ajh.25908.
    PubMed    


  98. RUAN GJ, Smith CJ, Day C, Harmsen WS, et al
    A Population-based Study of Chronic Eosinophilic Leukemia-Not Otherwise Specified in the United States.
    Am J Hematol. 2020 Jun 13. doi: 10.1002/ajh.25906.
    PubMed    


  99. HASTINGS A, Apperley JF, Nadal-Melsio E, Brown L, et al
    Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13).
    Am J Hematol. 2020 Jun 10. doi: 10.1002/ajh.25903.
    PubMed    


  100. JAIN P, Wang XI
    Carcinocythemia - cancer cell leukemia.
    Am J Hematol. 2020 Jun 10. doi: 10.1002/ajh.25902.
    PubMed    


  101. SAMRA B, Alotaibi AS, Short NJ, Khoury JD, et al
    Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Am J Hematol. 2020 Jun 5. doi: 10.1002/ajh.25896.
    PubMed    


  102. SUNG AD, Jauhari S, Siamakpour-Reihani S, Rao AV, et al
    Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
    Am J Hematol. 2020;95:662-671.
    PubMed     Abstract available


  103. PATEL SS, Weinberg OK
    Diagnostic workup of acute leukemias of ambiguous lineage.
    Am J Hematol. 2020;95:718-722.
    PubMed     Abstract available


    May 2020
  104. QASRAWI A, Ramlal R, Munker R, Hildebrandt GC, et al
    Prognostic impact of Philadelphia Chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome.
    Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25873.
    PubMed     Abstract available


  105. BYRNE M, Danielson N, Sengsayadeth S, Rasche A, et al
    The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
    Am J Hematol. 2020 May 10. doi: 10.1002/ajh.25859.
    PubMed     Abstract available


  106. AITKEN MJL, Benton CB, Wang F, Zhang J, et al
    33 years later: Two distinct cases of acute lymphoblastic leukemia in one patient.
    Am J Hematol. 2020 May 1. doi: 10.1002/ajh.25850.
    PubMed    


    April 2020
  107. SHORT NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, et al
    Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
    Am J Hematol. 2020 Apr 30. doi: 10.1002/ajh.25854.
    PubMed    


  108. CADENAS FL, Bua BR, Campelo MD, Rieu JB, et al
    A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25842.
    PubMed    


  109. CHRISTIAN S, Arain S, Patel P, Khan I, et al
    A Multi-institutional Comparison of Mitoxantrone, Etoposide, and Cytarabine (MEC) versus High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25838.
    PubMed     Abstract available


  110. MAFFINI E, Labopin M, Blaise D, Ciceri F, et al
    CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the Euro
    Am J Hematol. 2020 Apr 17. doi: 10.1002/ajh.25826.
    PubMed     Abstract available


  111. KLEINSTERN G, O'Brien DR, Li X, Tian S, et al
    Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.
    Am J Hematol. 2020 Apr 12. doi: 10.1002/ajh.25831.
    PubMed     Abstract available


  112. GIARDINO S, Peffault de Latour R, Aljurf M, Eikema DJ, et al
    Outcome of Patients with Fanconi Anemia developing myelodysplasia and acute leukemia who received Allogeneic Hematopoietic Stem Cell Transplantation: A retrospective analysis on Behalf of EBMT group.
    Am J Hematol. 2020 Apr 8. doi: 10.1002/ajh.25810.
    PubMed     Abstract available


  113. ROGERS HJ, Wang X, Xie Y, Davis AR, et al
    Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a Bone Marrow Pathology Group study.
    Am J Hematol. 2020 Apr 6. doi: 10.1002/ajh.25814.
    PubMed     Abstract available


  114. MORSIA E, Reichard K, Pardanani A, Tefferi A, et al
    WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25811.
    PubMed    


  115. ZHU HH, Yang MC, Wang F, Lou YJ, et al
    Identification of a novel NUP98-RARA fusion transcript as the 14(th) variant of acute promyelocytic leukemia.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25807.
    PubMed    


  116. LOSCOCCO GG, Mannelli F, Mannelli L, Vergoni F, et al
    A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: morphological and molecular characteristics of a highly aggressive disease.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25806.
    PubMed    


  117. KEMPS PG, Cleven AHG, van Wezel T, van Eijk R, et al
    B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25801.
    PubMed    


  118. JABBOUR E, Kantarjian H
    Chronic Myeloid Leukemia: 2020 Update on Diagnosis, Therapy and Monitoring.
    Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25792.
    PubMed     Abstract available


  119. OHANIAN M, Telouk P, Kornblau S, Albarede F, et al
    A heavy metal baseline score predicts outcome in acute myeloid leukemia.
    Am J Hematol. 2020;95:422-434.
    PubMed     Abstract available


  120. COLTRO G, Antelo G, Lasho TL, Finke CM, et al
    Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Am J Hematol. 2020;95:E86-E89.
    PubMed    


    March 2020
  121. BARON F, Efficace F, Cannella L, Muus P, et al
    Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: Long-term follow up of a phase III study.
    Am J Hematol. 2020 Mar 31. doi: 10.1002/ajh.25795.
    PubMed     Abstract available


  122. SASAKI K, Kantarjian H, Wierda W, Ravandi F, et al
    Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
    Am J Hematol. 2020 Mar 14. doi: 10.1002/ajh.25784.
    PubMed     Abstract available


  123. LIU H, Miao Y, Ferrajoli A, Tang G, et al
    Leukemic Phase of Richter transformation: A Mimic of Acute Myeloid Leukemia that Responded to Ibrutinib Monotherapy.
    Am J Hematol. 2020 Mar 12. doi: 10.1002/ajh.25782.
    PubMed     Abstract available


  124. HU KX, Du X, Guo M, Yu CL, et al
    Comparative study of micro-transplantation from HLA fully mismatched unrelated and partly matched related donors in acute myeloid leukemia.
    Am J Hematol. 2020 Mar 10. doi: 10.1002/ajh.25780.
    PubMed     Abstract available


  125. EVANS LA, Jevremovic D, Nandakumar B, Dispenzieri A, et al
    Utilizing Multiparametric Flow Cytometry in the Diagnosis of Patients with Primary Plasma Cell Leukemia.
    Am J Hematol. 2020 Mar 4. doi: 10.1002/ajh.25773.
    PubMed     Abstract available


  126. ZHAO Y, Mullenbach B, Wang E
    Isolated cerebrospinal fluid relapse of acute myeloid leukemia status post stem cell transplant: a neuroleukemiosis manifesting as polyneuropathy.
    Am J Hematol. 2020 Mar 2. doi: 10.1002/ajh.25772.
    PubMed    


  127. GARCIA JS, Bhatt S, Fell G, Sperling AS, et al
    Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
    Am J Hematol. 2020;95:245-250.
    PubMed     Abstract available


    February 2020
  128. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Class CA, Sasaki K, et al
    Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy.
    Am J Hematol. 2020 Feb 28. doi: 10.1002/ajh.25769.
    PubMed    


  129. HERISHANU Y, Shaulov A, Fineman R, BasiC-Kinda S, et al
    Frontline treatment with the combination obinutuzumab+/-chlorambucil for chronic lymphocytic leukemia outside clinical trials: results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
    Am J Hematol. 2020 Feb 25. doi: 10.1002/ajh.25766.
    PubMed     Abstract available


  130. STERLING C, Webster J
    "Harnessing the Immune System After Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia".
    Am J Hematol. 2020 Feb 5. doi: 10.1002/ajh.25750.
    PubMed     Abstract available


    January 2020
  131. MOORE J, Baran AM, Meacham PJ, Evans AG, et al
    Initial treatment of B-cell Prolymphocytic Leukemia with Ibrutinib.
    Am J Hematol. 2020 Jan 17. doi: 10.1002/ajh.25733.
    PubMed    


  132. ANAGNOSTOU T, Knudson RA, Pearce KE, Meyer RG, et al
    Clinical Utility of Fluorescence In Situ Hybridization-based Diagnosis of BCR-ABL1 like (Philadelphia Chromosome like) B-Acute Lymphoblastic Leukemia.
    Am J Hematol. 2020 Jan 9. doi: 10.1002/ajh.25729.
    PubMed    


  133. ZHU HH, Qian JJ, Sun WJ, You LS, et al
    Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation.
    Am J Hematol. 2020 Jan 7. doi: 10.1002/ajh.25719.
    PubMed    


  134. WILLIAMS AM, Baran AM, Schaffer M, Bushart J, et al
    Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
    Am J Hematol. 2020;95:E16-E18.
    PubMed    


    December 2019
  135. POIRE X, Labopin M, Polge E, Volin L, et al
    The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation.
    Am J Hematol. 2019 Dec 26. doi: 10.1002/ajh.25714.
    PubMed     Abstract available


  136. HAMPEL PJ, Call TG, Ding W, Muchtar E, et al
    Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: combination therapy to prevent ibrutinib flare.
    Am J Hematol. 2019 Dec 1. doi: 10.1002/ajh.25690.
    PubMed    


  137. MERLI M, Passamonti F
    A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
    Am J Hematol. 2019;94:1303-1305.
    PubMed    


    November 2019
  138. SZUBER N, Elliott M, Tefferi A
    Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management.
    Am J Hematol. 2019 Nov 25. doi: 10.1002/ajh.25688.
    PubMed     Abstract available


  139. ZHANG Z, Jiang M, Borthakur G, Luan S, et al
    Acute myeloid leukemia with a novel CPSF6-RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy.
    Am J Hematol. 2019 Nov 25. doi: 10.1002/ajh.25689.
    PubMed    


  140. PATNAIK MM, Tefferi A
    Chronic Myelomonocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Management.
    Am J Hematol. 2019 Nov 17. doi: 10.1002/ajh.25684.
    PubMed     Abstract available


  141. MATTSSON M, Sandin F, Kimby E, Hoglund M, et al
    Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise; a nationwide population-based study.
    Am J Hematol. 2019 Nov 14. doi: 10.1002/ajh.25681.
    PubMed    


  142. NALGHRANYAN S, Singh AP, Schinke C
    The Combination of Venetoclax, Daratumumab and Dexamethasone for the treatment of refractory primary plasma cell leukemia.
    Am J Hematol. 2019 Nov 10. doi: 10.1002/ajh.25676.
    PubMed    


  143. YILMAZ M, Kantarjian H, Wang X, Khoury JD, et al
    The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
    Am J Hematol. 2019 Nov 3. doi: 10.1002/ajh.25671.
    PubMed     Abstract available


  144. KOWALCZYK JR, Zawitkowska J, Lejman M, Drabko K, et al
    Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial.
    Am J Hematol. 2019;94:E307-E310.
    PubMed    


  145. MOLICA M, Breccia M, Foa R, Jabbour E, et al
    Maintenance therapy in AML: The past, the present and the future.
    Am J Hematol. 2019;94:1254-1265.
    PubMed     Abstract available


  146. NISHIWAKI S, Mizuta S, Ohashi K, Fukuda T, et al
    Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease.
    Am J Hematol. 2019;94:E301-E305.
    PubMed    


  147. AMBINDER AJ, Hambley B, Shanbhag S, Merrill SA, et al
    Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
    Am J Hematol. 2019;94:E296-E299.
    PubMed    


  148. PENTHER D, Etancelin P, Lusina D, Bidet A, et al
    Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features.
    Am J Hematol. 2019;94:E285-E288.
    PubMed    


  149. HAN X, Wang C, Zhou J
    Chimeric antigen receptor T (CAR-T) cells present with reactive and pleomorphic morphology in bone marrow.
    Am J Hematol. 2019;94:1297-1298.
    PubMed    


    October 2019
  150. KRAKOW EF, Gyurkocza B, Storer BE, Chauncey TR, et al
    Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.
    Am J Hematol. 2019 Oct 22. doi: 10.1002/ajh.25665.
    PubMed     Abstract available


  151. PEREZ-MARTINEZ A, Ferreras C, Pascual A, Gonzalez-Vicent M, et al
    Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish Working Group for Bone Marrow Transplantation in Children (GETMON) and the Spanish Grupo for Hematopoietic Transplantation (G
    Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25661.
    PubMed     Abstract available


  152. SROUR SA, Saliba RM, Bittencourt MC, Ramos Perez JM, et al
    Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation.
    Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25647.
    PubMed     Abstract available


  153. DALLE IA, Kantarjian HM, Short NJ, Konopleva M, et al
    Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
    Am J Hematol. 2019 Oct 8. doi: 10.1002/ajh.25648.
    PubMed     Abstract available


  154. MAITRE E, Cornet E, Troussard X
    Hairy cell leukemia 2020: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25653.
    PubMed     Abstract available


  155. LUBOWIECKI M, Siow W, Eagleton H, Bain BJ, et al
    Large granular lymphocytic leukemia as a cause of pancytopenia.
    Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25650.
    PubMed    


  156. OFRAN Y, Hayun M, Leiba R, Zuckerman T, et al
    Bone marrow blast elimination by the fifth day of 7+3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.
    Am J Hematol. 2019 Oct 7. doi: 10.1002/ajh.25651.
    PubMed    


    September 2019
  157. MUNIR T, Brown JR, O'Brien S, Barrientos JC, et al
    Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Am J Hematol. 2019 Sep 11. doi: 10.1002/ajh.25638.
    PubMed     Abstract available


  158. FLINN IW, Cherry MA, Maris MB, Matous JV, et al
    Combination Trial of Duvelisib (IPI-145) with Rituximab or Bendamustine/Rituximab in Patients with Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia.
    Am J Hematol. 2019 Sep 6. doi: 10.1002/ajh.25634.
    PubMed     Abstract available


  159. TU S, Huang R, Guo Z, Deng L, et al
    Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CRES or severe CRS.
    Am J Hematol. 2019 Sep 5. doi: 10.1002/ajh.25630.
    PubMed    


  160. MANOHAR S, Bansal A, Wanchoo R, Sakhiya V, et al
    Ibrutinib induced acute tubular injury: A case series and review of the literature.
    Am J Hematol. 2019;94:E223-E225.
    PubMed    


    August 2019
  161. LAUSEKER M, Bachl K, Turkina A, Faber E, et al
    Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
    Am J Hematol. 2019 Aug 27. doi: 10.1002/ajh.25628.
    PubMed     Abstract available


  162. TOMLINSON BK, Tuscano JM, Abedi M, Welborn J, et al
    A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.
    Am J Hematol. 2019 Aug 4. doi: 10.1002/ajh.25605.
    PubMed    


  163. PATEL SS, Pinkus GS, Ritterhouse LL, Segal JP, et al
    High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.
    Am J Hematol. 2019;94:921-928.
    PubMed     Abstract available


  164. DUNLAP JB, Leonard J, Rosenberg M, Cook R, et al
    The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.
    Am J Hematol. 2019;94:913-920.
    PubMed     Abstract available


  165. JUST VINHOLT P, Hojrup Knudsen G, Sperling S, Frederiksen H, et al
    Platelet function tests predict bleeding in patients with acute myeloid leukemia and thrombocytopenia.
    Am J Hematol. 2019;94:891-901.
    PubMed     Abstract available


    July 2019
  166. IURLO A, Bucelli C, Cattaneo D, Levati GV, et al
    UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia.
    Am J Hematol. 2019 Jul 30. doi: 10.1002/ajh.25596.
    PubMed    


  167. HALLEK M
    Chronic lymphocytic leukemia: 2019 update on diagnosis, risk stratification and treatment.
    Am J Hematol. 2019 Jul 30. doi: 10.1002/ajh.25595.
    PubMed     Abstract available


  168. MOYERS JT, Liu LW, Ossowski S, Goddard L, et al
    A Rash in a Hairy Situation: Leukocytoclastic Vasculitis at Presentation of Hairy Cell Leukemia.
    Am J Hematol. 2019 Jul 30. doi: 10.1002/ajh.25597.
    PubMed    


  169. CUNNINGHAM I, Hamele-Bena D, Guo Y, Shiomi T, et al
    Extramedullary Leukemia Behaving as Solid Cancer: Clinical, Histologic, and Genetic Clues to Chemoresistance in Organ Sites.
    Am J Hematol. 2019 Jul 28. doi: 10.1002/ajh.25594.
    PubMed     Abstract available


  170. JIANG H, Li C, Yin P, Guo T, et al
    Anti-CD19 CAR-T Therapy Bridging to Allo-HSCT for Relapsed/refractory B-cell Acute Lymphoblastic Leukemia: An Open-Label Pragmatic Clinical Trial.
    Am J Hematol. 2019 Jul 18. doi: 10.1002/ajh.25582.
    PubMed     Abstract available


  171. IACCARINO L, Ottone T, Alfonso V, Cicconi L, et al
    Mutational landscape of patients with Acute Promyelocytic Leukemia at diagnosis and relapse.
    Am J Hematol. 2019 Jul 10. doi: 10.1002/ajh.25573.
    PubMed     Abstract available


  172. GONG Z, Xu ML, Chen M, Cui W, et al
    Philadelphia chromosome-negative acute leukemia in chronic myeloid leukemia.
    Am J Hematol. 2019 Jul 4. doi: 10.1002/ajh.25571.
    PubMed    


  173. ALDOSS I, Yang D, Pillai R, Sanchez JF, et al
    Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
    Am J Hematol. 2019 Jul 1. doi: 10.1002/ajh.25567.
    PubMed    


  174. STRATI P, Garcia-Manero G, Zhao C, Kadia T, et al
    Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts.
    Am J Hematol. 2019;94:E188-E190.
    PubMed    


  175. KOUTSILIERI S, Caudle KE, Alzghari SK, Monte AA, et al
    Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango.
    Am J Hematol. 2019;94:737-740.
    PubMed    


  176. QUINQUENEL A, Godet S, Dartigeas C, Ysebaert L, et al
    Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO group.
    Am J Hematol. 2019;94:E183-E185.
    PubMed    


    June 2019
  177. AL-SAWAF O, Bazeos A, Robrecht S, Bahlo J, et al
    Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
    Am J Hematol. 2019 Jun 20. doi: 10.1002/ajh.25561.
    PubMed     Abstract available


  178. YALNIZ F, Abou Dalle I, Kantarjian H, Borthakur G, et al
    Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib.
    Am J Hematol. 2019 Jun 10. doi: 10.1002/ajh.25553.
    PubMed     Abstract available


  179. POLLYEA DA
    Acute Myeloid Leukemia Drug Development in the Post-Venetoclax Era.
    Am J Hematol. 2019 Jun 9. doi: 10.1002/ajh.25556.
    PubMed    


    May 2019
  180. PRESS RD, Eickelberg G, Froman A, Yang F, et al
    NGS-Defined Minimal Residual Disease Before Stem Cell Transplantation Predicts Acute Myeloid Leukemia Relapse.
    Am J Hematol. 2019 May 23. doi: 10.1002/ajh.25514.
    PubMed     Abstract available


  181. PICHLER H, Lawitschka A, Glogova E, Willasch AM, et al
    Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia - A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP.
    Am J Hematol. 2019 May 16. doi: 10.1002/ajh.25511.
    PubMed     Abstract available


  182. O'BRIEN SM, Byrd JC, Hillmen P, Coutre S, et al
    Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
    Am J Hematol. 2019;94:554-562.
    PubMed     Abstract available


  183. ZHAO XS, Liu YR, Xu LP, Wang Y, et al
    Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts.
    Am J Hematol. 2019;94:512-521.
    PubMed     Abstract available


    April 2019
  184. COSTON T, Pophali P, Vallapureddy R, Lasho TL, et al
    Suboptimal Response Rates to Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia; a Single Institutional Study of 121 Patients.
    Am J Hematol. 2019 Apr 9. doi: 10.1002/ajh.25488.
    PubMed     Abstract available


  185. MEDEIROS BC, Chan SM, Daver NG, Jonas BA, et al
    Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.
    Am J Hematol. 2019 Apr 3. doi: 10.1002/ajh.25484.
    PubMed     Abstract available


  186. HAMLIN PA, Flinn IW, Wagner-Johnston N, Burger JA, et al
    Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
    Am J Hematol. 2019;94:E90-E93.
    PubMed    


    March 2019
  187. LI N, Wang SA, Lin P, Jabbour E, et al
    Relapsed B-Acute Lymphoblastic Leukemia with Aberrant Myeloperoxidase Expression Following CAR T-cell Therapy: A Diagnostic Challenge.
    Am J Hematol. 2019 Mar 27. doi: 10.1002/ajh.25478.
    PubMed    


  188. BOHN JP, Pircher A, Wanner D, Vill D, et al
    Low-dose vemurafenib in hairy cell leukemia patients with active infection.
    Am J Hematol. 2019 Mar 27. doi: 10.1002/ajh.25474.
    PubMed    


  189. LEUNG GMK, Zhang C, Ng NKL, Yang N, et al
    Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations.
    Am J Hematol. 2019 Mar 22. doi: 10.1002/ajh.25469.
    PubMed     Abstract available


  190. BHATT VR, Shostrom V, Armitage JO, Gundabolu K, et al
    Treatment patterns and outcomes of octogenarian patients with acute myeloid leukemia.
    Am J Hematol. 2019 Mar 18. doi: 10.1002/ajh.25464.
    PubMed    


  191. BAIR SM, Porter DL
    Accelerating CAR therapy in CLL: The development and challenges of CAR T cell therapy for chronic lymphocytic leukemia.
    Am J Hematol. 2019 Mar 12. doi: 10.1002/ajh.25457.
    PubMed     Abstract available


  192. ABBAS HA, Ravandi F, Loghavi S, Patel KP, et al
    NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated AML.
    Am J Hematol. 2019 Mar 5. doi: 10.1002/ajh.25454.
    PubMed    


  193. FURUTANI E, Newburger PE, Shimamura A
    Neutropenia in the age of genetic testing: Advances and challenges.
    Am J Hematol. 2019;94:384-393.
    PubMed     Abstract available


  194. CORTES J, Rea D, Lipton JH
    Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Am J Hematol. 2019;94:346-357.
    PubMed     Abstract available


    February 2019
  195. FREY NV
    CAR T cells for Acute Lymphoblastic Leukemia.
    Am J Hematol. 2019 Feb 19. doi: 10.1002/ajh.25442.
    PubMed     Abstract available


  196. SAWAYAMA Y, Itonaga H, Fukushima T, Nakano N, et al
    Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.
    Am J Hematol. 2019 Feb 17. doi: 10.1002/ajh.25438.
    PubMed    


  197. CALDWELL I, Ruskova A, Royle G, Liang J, et al
    Pure erythroid leukemia: The value of E-cadherin in making the diagnosis.
    Am J Hematol. 2019 Feb 17. doi: 10.1002/ajh.25437.
    PubMed    


  198. SUI JN, Chen QS, Zhang YX, Sheng Y, et al
    Identifying Leukemia-Associated Immunophenotype-based Individualized Minimal Residual Disease in Acute Myeloid Leukemia and its Prognostic Significance.
    Am J Hematol. 2019 Feb 7. doi: 10.1002/ajh.25431.
    PubMed     Abstract available


    January 2019
  199. QASIM W
    Allogeneic CAR T cell therapies for leukemia - R1.
    Am J Hematol. 2019 Jan 11. doi: 10.1002/ajh.25399.
    PubMed     Abstract available


  200. JABBOUR E, Advani AS, Stelljes M, Stock W, et al
    Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
    Am J Hematol. 2019 Jan 8. doi: 10.1002/ajh.25394.
    PubMed     Abstract available


  201. SZARZYNSKA-ZAWADZKA B, Kunz J, Sedek L, Kosmalska M, et al
    PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols.
    Am J Hematol. 2019 Jan 7. doi: 10.1002/ajh.25396.
    PubMed    


  202. EL CHAER F, Ali OM, Sausville EA, Law JY, et al
    Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab.
    Am J Hematol. 2019;94:E7-E8.
    PubMed    


    December 2018
  203. LEE CJ, Labopin M, Beelen D, Finke J, et al
    Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT.
    Am J Hematol. 2018 Dec 30. doi: 10.1002/ajh.25395.
    PubMed     Abstract available


  204. FANG H, Reichard KK, Rabe KG, Hanson CA, et al
    IGH translocations in chronic lymphocytic leukemia (CLL): clinicopathologic features and clinical outcomes.
    Am J Hematol. 2018 Dec 21. doi: 10.1002/ajh.25385.
    PubMed     Abstract available


  205. ANAND K, Kumar P, Pingali SR, Pati D, et al
    Acute Myeloid Leukemia with Eosinophilia (AML-M4Eo) after Cyclin Dependent Kinases 4/6 Inhibitor Treatment Due to Underlying Clonal Hematopoiesis of Indeterminate Potential (CHIP).
    Am J Hematol. 2018 Dec 21. doi: 10.1002/ajh.25380.
    PubMed    


    November 2018
  206. MEI M, Aldoss I, Marcucci G, Pullarkat V, et al
    Hypomethylating Agents in combination with Venetoclax for Acute Myeloid Leukemia: Update on Clinical trial data and Practical Considerations for use.
    Am J Hematol. 2018 Nov 30. doi: 10.1002/ajh.25369.
    PubMed     Abstract available


  207. POIRE X, Labopin M, Polge E, Blaise D, et al
    Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission.
    Am J Hematol. 2018 Nov 19. doi: 10.1002/ajh.25355.
    PubMed     Abstract available


  208. ANDREANI G, Dragani M, Serra A, Nicoli P, et al
    Venetoclax plus Decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
    Am J Hematol. 2018 Nov 15. doi: 10.1002/ajh.25352.
    PubMed    


  209. SHANMUGAM V, Dorfman DM
    Acute myeloid leukemia with minimal differentiation (AML M0) mimicking acute lymphoblastic leukemia.
    Am J Hematol. 2018 Nov 15. doi: 10.1002/ajh.25354.
    PubMed    


  210. SAINI N, Cerny J, Furtado V, Desmond A, et al
    Elderly do benefit from induction chemotherapy: High dose mitoxantrone based ("5+1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2018 Nov 12. doi: 10.1002/ajh.25347.
    PubMed     Abstract available


  211. SHORT NJ, Jabbour E, Albitar M, de Lima M, et al
    Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts.
    Am J Hematol. 2018 Nov 5. doi: 10.1002/ajh.25338.
    PubMed     Abstract available


    October 2018
  212. BAHASHWAN S, Molucon-Chabrot C, Hermet E, Ravinet A, et al
    Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25332.
    PubMed    


  213. LITZOW MR, Wang XV, Carroll MP, Karp JE, et al
    A Randomized Trial of Three Novel Regimens for Recurrent Acute Myeloid Leukemia Demonstrates the Continuing Challenge of Treating this Difficult Disease.
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25333.
    PubMed     Abstract available


  214. JELINEK T, Mihalyova J, Kascak M, Duras J, et al
    Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t[11;14].
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25331.
    PubMed    


  215. KONUMA T, Harada K, Yamasaki S, Mizuno S, et al
    Upfront allogeneic HCT vs remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: a propensity score matched analysis.
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25336.
    PubMed     Abstract available


  216. LOEFF FC, Rijs K, van Egmond EHM, Zoutman WH, et al
    Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25337.
    PubMed     Abstract available


  217. RENAUD L, Nibourel O, Marceau-Renaut A, Gruson B, et al
    Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: a study of the French Hauts-de-France AML observatory.
    Am J Hematol. 2018 Oct 25. doi: 10.1002/ajh.25328.
    PubMed    


  218. SHORT NJ, Jabbour E, Naqvi K, Patel A, et al
    A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
    Am J Hematol. 2018 Oct 17. doi: 10.1002/ajh.25318.
    PubMed     Abstract available


  219. HEHLMANN R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, et al
    Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-Phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY.
    Am J Hematol. 2018 Oct 5. doi: 10.1002/ajh.25306.
    PubMed     Abstract available


  220. ESTEY EH
    Acute myeloid leukemia: 2019 update on risk-stratification and management.
    Am J Hematol. 2018;93:1267-1291.
    PubMed     Abstract available


    September 2018
  221. BEGNA KH, Ali W, Gangat N, Elliott MA, et al
    A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.
    Am J Hematol. 2018 Sep 19. doi: 10.1002/ajh.25290.
    PubMed    


  222. CHRISTOPEIT M, Labopin M, Gorin NC, Saraceni F, et al
    Allogeneic Stem Cell Transplantation following Relapse post Autologous Stem Cell Transplantation in adult patients with Acute Myeloid Leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
    Am J Hematol. 2018 Sep 14. doi: 10.1002/ajh.25285.
    PubMed     Abstract available


  223. JACOBY E, Bielorai B, Avigdor A, Itzhaki O, et al
    Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
    Am J Hematol. 2018 Sep 6. doi: 10.1002/ajh.25274.
    PubMed     Abstract available


    August 2018
  224. YANG MH, Wan WQ, Luo JS, Zheng MC, et al
    Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study.
    Am J Hematol. 2018 Aug 30. doi: 10.1002/ajh.25271.
    PubMed     Abstract available


  225. JAIN P, Kanagal-Shamanna R, Konoplev SN, Zuo Z, et al
    Biclonal IGHV-4-34 variant hairy cell leukemia and CLL - successful treatment with ibrutinib and venetoclax.
    Am J Hematol. 2018 Aug 28. doi: 10.1002/ajh.25264.
    PubMed    


  226. HOW J, Vij KR, Ebadi M, DeFor TE, et al
    Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Am J Hematol. 2018 Aug 24. doi: 10.1002/ajh.25262.
    PubMed    


  227. ROBAK T, Burger JA, Tedeschi A, Barr PM, et al
    Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies.
    Am J Hematol. 2018 Aug 20. doi: 10.1002/ajh.25259.
    PubMed     Abstract available


  228. ASSI R, Gur HD, Loghavi S, Konoplev SN, et al
    P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival.
    Am J Hematol. 2018 Aug 16. doi: 10.1002/ajh.25255.
    PubMed     Abstract available


  229. MI X, Griffin G, Lee W, Patel S, et al
    Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations.
    Am J Hematol. 2018 Aug 16. doi: 10.1002/ajh.25256.
    PubMed     Abstract available


  230. CUNNINGHAM I, Worthley D, Gastroenterologist C
    LEUKEMIA IN GI ORGANS AS CAUSE OF TREATMENT FAILURE: 378 CASES ANALYZED.
    Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25250.
    PubMed     Abstract available


  231. HO G, Li Q, Brunson A, Jonas BA, et al
    Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia treated in California.
    Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25252.
    PubMed    


  232. POPHALI P, Horna P, Lasho TL, Finke CM, et al
    Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of 39 patients.
    Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25246.
    PubMed     Abstract available


  233. XIA D, Hsi ED, Cin PD, Hasserjian RP, et al
    Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation.
    Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25249.
    PubMed    


  234. O'BRIEN S, Patel M, Kahl BS, Horwitz SM, et al
    Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study.
    Am J Hematol. 2018 Aug 10. doi: 10.1002/ajh.25243.
    PubMed     Abstract available


  235. ABAZA Y, Cortes J, Ravandi F, Kadia T, et al
    Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.
    Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25240.
    PubMed     Abstract available


  236. ELLIOTT MA, Tefferi A
    Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.
    Am J Hematol. 2018;93:578-587.
    PubMed     Abstract available


    July 2018
  237. SIEGEL SE, Advani A, Seibel N, Muffly L, et al
    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens.
    Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25229.
    PubMed     Abstract available


  238. ROSENTHAL J, Naqvi AS, Luo M, Wertheim G, et al
    Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.
    Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25235.
    PubMed     Abstract available


  239. SARACENI F, Beohou E, Labopin M, Arcese W, et al
    Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    Am J Hematol. 2018 Jul 23. doi: 10.1002/ajh.25225.
    PubMed     Abstract available


  240. OHANIAN M, Garcia-Manero G, Levis M, Jabbour E, et al
    Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML).
    Am J Hematol. 2018 Jul 20. doi: 10.1002/ajh.25198.
    PubMed     Abstract available


  241. NORWOOD J, Pastoret C, Luycx O, Le Coz MF, et al
    Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life.
    Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25217.
    PubMed    


  242. FATHI AT, Hobbs G, Dey BR, Chen YB, et al
    Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia.
    Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25218.
    PubMed    


  243. MORABITO F, Shanafelt TD, Gentile M, Reda G, et al
    Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases.
    Am J Hematol. 2018 Jul 9. doi: 10.1002/ajh.25206.
    PubMed    


  244. GILLEECE MH, Labopin M, Yakoub-Agha I, Volin L, et al
    Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Part
    Am J Hematol. 2018 Jul 7. doi: 10.1002/ajh.25211.
    PubMed     Abstract available


    June 2018
  245. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
    Am J Hematol. 2018;93:824-840.
    PubMed     Abstract available


    May 2018
  246. CHYLA B, Daver N, Doyle K, McKeegan E, et al
    Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia.
    Am J Hematol. 2018 May 17. doi: 10.1002/ajh.25146.
    PubMed    


  247. BACIGALUPO A, Van Lint MT, Sica S, Laurenti L, et al
    High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study.
    Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25131.
    PubMed    


    April 2018
  248. SIEGELE BJ, Nardi V
    Laboratory Testing in BCR-ABL1-like (Philadelphia-like) B-Lymphoblastic Leukemia/Lymphoma.
    Am J Hematol. 2018 Apr 26. doi: 10.1002/ajh.25126.
    PubMed     Abstract available


  249. CUI L, Li ZG, Chai YH, Yu J, et al
    Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
    Am J Hematol. 2018 Apr 20. doi: 10.1002/ajh.25124.
    PubMed     Abstract available


  250. GORIN NC, Labopin M, Blaise D, Dumas PY, et al
    Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia: Better Outcomes with Busulfan and Melphalan compared with Busulfan and Cyclophosphamide in high Risk Patients autografted in First Complete Re
    Am J Hematol. 2018 Apr 12. doi: 10.1002/ajh.25105.
    PubMed     Abstract available


  251. CAO J, Wang G, Cheng H, Wei C, et al
    Potent anti-leukemia activities of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2018 Apr 10. doi: 10.1002/ajh.25108.
    PubMed     Abstract available


  252. PUNGOLINO E, Rossi G, De Canal G, Trojani A, et al
    Nilotinib induced Bone Marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia.
    Am J Hematol. 2018 Apr 10. doi: 10.1002/ajh.25106.
    PubMed    


  253. CAOCCI G, Mulas O, Annunziata M, Luciano L, et al
    Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
    Am J Hematol. 2018 Apr 6. doi: 10.1002/ajh.25102.
    PubMed    


    March 2018
  254. JIN CH, Li Y, Xia J, Li Y, et al
    CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.
    Am J Hematol. 2018 Mar 30. doi: 10.1002/ajh.25099.
    PubMed     Abstract available


  255. CZYZ A, Labopin M, Giebel S, Socie G, et al
    Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Soc
    Am J Hematol. 2018 Mar 25. doi: 10.1002/ajh.25091.
    PubMed     Abstract available


  256. LI Z, Labopin M, Ciceri F, Blaise D, et al
    Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study.
    Am J Hematol. 2018 Mar 14. doi: 10.1002/ajh.25087.
    PubMed     Abstract available


  257. OGDEN J, Yui J, Ali W, Mudireddy M, et al
    Pre-Anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia.
    Am J Hematol. 2018 Mar 6. doi: 10.1002/ajh.25083.
    PubMed    


  258. CANAANI J, Labopin M, Huang XJ, Arcese W, et al
    T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia. A report from the Acute Leukemia Working Party of the EBMT.
    Am J Hematol. 2018 Mar 2. doi: 10.1002/ajh.25082.
    PubMed     Abstract available


  259. JABBOUR E, Kantarjian H
    Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
    Am J Hematol. 2018;93:442-459.
    PubMed     Abstract available


    February 2018
  260. KHODER A, Al Obaidi M, Babb A, Liu C, et al
    Chronic neutrophilic leukemia.
    Am J Hematol. 2018 Feb 23. doi: 10.1002/ajh.25073.
    PubMed    


  261. WIERZBOWSKA A, Wawrzyniak E, Pluta A, Robak T, et al
    Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial.
    Am J Hematol. 2018 Feb 8. doi: 10.1002/ajh.25062.
    PubMed    


  262. OTTONE T, Alfonso V, Iaccarino L, Hasan SK, et al
    Longitudinal detection of DNMT3A(R882H) transcripts in patients with acute myeloid leukemia.
    Am J Hematol. 2018 Feb 8. doi: 10.1002/ajh.25061.
    PubMed    


  263. BORLENGHI E, Pagani C, Zappasodi P, Bernardi M, et al
    Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL).
    Am J Hematol. 2018;93:E54-E57.
    PubMed    


  264. GENTILE M, Shanafelt TD, Mauro FR, Laurenti L, et al
    Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.
    Am J Hematol. 2018;93:E35-E37.
    PubMed    


    January 2018
  265. HERGOTT CB, Pozdnyakova O
    Evans syndrome secondary to undiagnosed chronic lymphocytic leukemia in a patient with unexplained bleeding.
    Am J Hematol. 2018 Jan 17. doi: 10.1002/ajh.25039.
    PubMed    


  266. CASSADAY RD, Stevenson PA, Wood BL, Becker PS, et al
    Description and Prognostic Significance of the Kinetics of Minimal Residual Disease Status in Adults with Acute Lymphoblastic Leukemia Treated with HyperCVAD.
    Am J Hematol. 2018 Jan 10. doi: 10.1002/ajh.25030.
    PubMed     Abstract available


  267. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults.
    Am J Hematol. 2018;93:47-57.
    PubMed     Abstract available


  268. BARRETT A, Catherwood M, Thornton P, Murphy P, et al
    Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy.
    Am J Hematol. 2018;93:E16-E17.
    PubMed    


  269. GUILLERMIN Y, Herbaux C, Subtil F, Aurran-Schleinitz T, et al
    Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
    Am J Hematol. 2018;93:E24-E27.
    PubMed    


  270. CALDWELL I, Ruskova A, Eaddy N, Bain BJ, et al
    Acute leukemic transformation of myelodysplastic syndrome: Is cytochemistry still relevant?
    Am J Hematol. 2018;93:148-149.
    PubMed    


    December 2017
  271. ASSI R, Ravandi F
    FLT3 Inhibitors in Acute Myeloid Leukemia: Choosing the Best when the Optimal Does Not Exist.
    Am J Hematol. 2017 Dec 29. doi: 10.1002/ajh.25027.
    PubMed     Abstract available


  272. DECROOCQ J, Itzykson R, Vigouroux S, Michallet M, et al
    Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cel
    Am J Hematol. 2017 Dec 11. doi: 10.1002/ajh.25004.
    PubMed     Abstract available


  273. BAIN BJ
    Pure erythroid leukemia.
    Am J Hematol. 2017 Dec 11. doi: 10.1002/ajh.25005.
    PubMed    


  274. DINARDO CD, Rausch CR, Benton C, Kadia T, et al
    Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies.
    Am J Hematol. 2017 Dec 8. doi: 10.1002/ajh.25000.
    PubMed     Abstract available


  275. TROUSSARD X, Cornet E
    Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2017;92:1382-1390.
    PubMed     Abstract available


  276. CHAPIRO E, Lesty C, Gabillaud C, Durot E, et al
    "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
    Am J Hematol. 2017 Dec 1. doi: 10.1002/ajh.24990.
    PubMed     Abstract available


  277. MOLICA M, Canichella M, Alunni Fegatelli D, Colafigli G, et al
    The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.
    Am J Hematol. 2017;92:E661-E664.
    PubMed    


  278. KOBAYASHI T, Nannya Y, Ichikawa M, Oritani K, et al
    A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
    Am J Hematol. 2017;92:1324-1332.
    PubMed     Abstract available


    November 2017
  279. JABBOUR E, Dull J, Yilmaz M, Khoury JD, et al
    Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression.
    Am J Hematol. 2017 Nov 27. doi: 10.1002/ajh.24987.
    PubMed     Abstract available


  280. RIBES D, El Hachem H, Oberic L, Vergez F, et al
    Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
    Am J Hematol. 2017 Nov 23. doi: 10.1002/ajh.24984.
    PubMed     Abstract available


  281. GODET S, Protin C, Dupuis J, Dartigeas C, et al
    Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2017 Nov 22. doi: 10.1002/ajh.24981.
    PubMed    


  282. WALTER RB, Michaelis LC, Othus M, Uy GL, et al
    Intergroup LEAP Trial (S1612): A Randomized Phase 2/3 Platform Trial to Test Novel Therapeutics in Medically Less Fit Older Adults with Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 22. doi: 10.1002/ajh.24980.
    PubMed    


  283. VENTON G, Courtier F, Charbonnier A, D'Incan E, et al
    Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Am J Hematol. 2017 Nov 17. doi: 10.1002/ajh.24973.
    PubMed     Abstract available


  284. ALTMAN JK, Foran JM, Pratz KW, Trone D, et al
    Phase 1 Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 15. doi: 10.1002/ajh.24974.
    PubMed     Abstract available


  285. DEANGELO DJ, Brunner AM, Werner L, Avigan D, et al
    A Phase I Study of Lenalidomide plus Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients with Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 9. doi: 10.1002/ajh.24968.
    PubMed     Abstract available


  286. CANAANI J, Savani BN, Labopin M, Huang XJ, et al
    Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.
    Am J Hematol. 2017 Nov 8. doi: 10.1002/ajh.24963.
    PubMed     Abstract available


  287. SANDMAIER BM, Khaled S, Oran B, Gammon G, et al
    Results of a Phase 1 Study of Quizartinib as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Stem Cell Transplant.
    Am J Hematol. 2017 Nov 1. doi: 10.1002/ajh.24959.
    PubMed     Abstract available


    October 2017
  288. MINETTO P, Guolo F, Clavio M, Kunkl A, et al
    A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.
    Am J Hematol. 2017 Oct 28. doi: 10.1002/ajh.24956.
    PubMed    


  289. COOMBS CC, Mathews SP
    Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently.
    Am J Hematol. 2017 Oct 20. doi: 10.1002/ajh.24950.
    PubMed    


  290. ABAZA Y, Kantarjian HM, Faderl S, Jabbour E, et al
    Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma.
    Am J Hematol. 2017 Oct 19. doi: 10.1002/ajh.24947.
    PubMed     Abstract available


  291. ALHURAIJI A, Kantarjian H, Boddu P, Ravandi F, et al
    Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24943.
    PubMed     Abstract available


  292. KHODER A, Al Obaidi M, Wiles N, Nadal-Melsio E, et al
    Lymphoplasmacytoid cytology in plasma cell leukemia.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24940.
    PubMed    


  293. TEFFERI A, Hanson CA, Ketterling RP
    Revisiting the need for bone marrow examination in chronic myeloid leukemia.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24942.
    PubMed    


  294. PATNAIK MM, Vallapureddy R, Yalniz FF, Hanson CA, et al
    Therapy Related-Chronic Myelomonocytic Leukemia (CMML): Molecular, Cytogenetic and Clinical Distinctions from de novo CMML.
    Am J Hematol. 2017 Oct 11. doi: 10.1002/ajh.24939.
    PubMed     Abstract available


  295. IZZI V, Lakkala J, Devarajan R, Savolainen ER, et al
    Vanin 1 (VNN1) levels predict poor outcome in acute myeloid leukemia.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24925.
    PubMed    


  296. LAZAREVIC VL, Labopin M, Wu D, Yakoub-Agha I, et al
    Relatively favourable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24928.
    PubMed     Abstract available


  297. EL FAKIH R, Jabbour E, Ravandi F, Hassanein M, et al
    Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24926.
    PubMed     Abstract available


  298. SPERR WR, Herndlhofer S, Gleixner K, Girschikofsky M, et al
    Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients >/=60 years.
    Am J Hematol. 2017;92:E567-E574.
    PubMed     Abstract available


  299. RASHIDI A, Linden MA, DeFor TE, Warlick E, et al
    History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Am J Hematol. 2017;92:1032-1036.
    PubMed     Abstract available


  300. SHIMONI A, Vago L, Bernardi M, Yerushalmi R, et al
    Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    Am J Hematol. 2017;92:1011-1019.
    PubMed     Abstract available


  301. MOLOGNI L, Piazza R, Khandelwal P, Pirola A, et al
    Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.
    Am J Hematol. 2017;92:E623-E625.
    PubMed    


  302. JAIN P, Burger JA, Khoury JD
    CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.
    Am J Hematol. 2017;92:1113-1114.
    PubMed    


    September 2017
  303. GAKSCH L, Kashofer K, Heitzer E, Quehenberger F, et al
    Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
    Am J Hematol. 2017 Sep 29. doi: 10.1002/ajh.24922.
    PubMed     Abstract available


  304. BRECCIA M, Colafigli G, Molica M, Scalzulli E, et al
    Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.
    Am J Hematol. 2017 Sep 28. doi: 10.1002/ajh.24916.
    PubMed    


  305. HAMPEL PJ, Chaffee KG, King RL, Simonetto D, et al
    Liver Dysfunction in Chronic Lymphocytic Leukemia: Prevalence, Outcomes, and Pathological Findings.
    Am J Hematol. 2017 Sep 22. doi: 10.1002/ajh.24915.
    PubMed     Abstract available


  306. CHANG YJ, Zhao XS, Wang Y, Liu YR, et al
    Effects of Pre- and Post-transplantation Minimal Residual Disease on Outcomes in Pediatric Patients with Acute Myeloid Leukemia Receiving Human Leukocyte Antigen-matched or Mismatched Related Donor Allografts.
    Am J Hematol. 2017 Sep 20. doi: 10.1002/ajh.24910.
    PubMed    


  307. GORIN NC, Labopin M, Pabst T, Remenyi P, et al
    Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.
    Am J Hematol. 2017 Sep 11. doi: 10.1002/ajh.24904.
    PubMed     Abstract available


  308. HALLEK M
    Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Am J Hematol. 2017;92:946-965.
    PubMed     Abstract available


  309. PERERA LP, Zhang M, Nakagawa M, Petrus MN, et al
    Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.
    Am J Hematol. 2017;92:892-901.
    PubMed     Abstract available


  310. BEHRENS M, Chowdry RP, Saba S, Saba NS, et al
    A centrocyte blood count of a quarter million.
    Am J Hematol. 2017;92:972-973.
    PubMed    


    August 2017
  311. SHI CR, Nambudiri VE
    Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
    Am J Hematol. 2017 Aug 24. doi: 10.1002/ajh.24894.
    PubMed    


  312. GOLDBERG SL, Cortes J, Gambacorti-Passerini C, Hehlmann R, et al
    First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
    Am J Hematol. 2017 Aug 17. doi: 10.1002/ajh.24887.
    PubMed     Abstract available


  313. COLTRO G, Mannelli F, Guglielmelli P, Pacilli A, et al
    A life-threatening ruxolitinib discontinuation syndrome.
    Am J Hematol. 2017;92:833-838.
    PubMed    


  314. YSEBAERT L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, et al
    Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
    Am J Hematol. 2017;92:E166-E168.
    PubMed    


    July 2017
  315. BEGNA K, Al-Kali A, Elliott M, Foran J, et al
    Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
    Am J Hematol. 2017 Jul 21. doi: 10.1002/ajh.24866.
    PubMed    


  316. BAIN BJ
    Pure erythroid leukemia: the need gather data on this condition as defined in the World Health Organisation classification.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24863.
    PubMed    


  317. VALLAPUREDDY R, Lasho TL, Hoversten K, Finke CM, et al
    Nucleophosmin 1 (NPM1) Mutations in Chronic Myelomonocytic Leukemia and Their Prognostic Relevance.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24861.
    PubMed    


  318. WANG W, Wang S, Medeiros LJ, Khoury JD, et al
    Response to Dr. Bain's comment on our review article: Pure Erythroid Leukemia.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24862.
    PubMed    


  319. JAROSOVA M, Hruba M, Oltova A, Plevova K, et al
    Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.
    Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24852.
    PubMed    


  320. KLIL-DRORI AJ, Yin H, Azoulay L, Harnois M, et al
    Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
    Am J Hematol. 2017 Jul 3. doi: 10.1002/ajh.24838.
    PubMed    


  321. RHEE SJ, Lee JW, Yu KS, Hong KT, et al
    Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Am J Hematol. 2017;92:607-613.
    PubMed     Abstract available


    June 2017
  322. JAIN P, Kantarjian H, Jain N, Short NJ, et al
    Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens.
    Am J Hematol. 2017 Jun 24. doi: 10.1002/ajh.24833.
    PubMed    


  323. LEVIN A, Kleman A, Rein L, Tarima S, et al
    Early Mortality in Patients with Acute Myelogenous Leukemia Treated in Teaching versus Non-teaching Hospitals: A Large Database Analysis.
    Am J Hematol. 2017 Jun 20. doi: 10.1002/ajh.24825.
    PubMed    


  324. EDER S, Canaani J, Beohou E, Labopin M, et al
    Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Socie
    Am J Hematol. 2017 Jun 14. doi: 10.1002/ajh.24823.
    PubMed     Abstract available


  325. TERRY CM, Shallis RM, Estey E, Lim SH, et al
    Day 14 bone marrow examination in the management of acute myeloid leukemia.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24818.
    PubMed     Abstract available


  326. BAZIN J, Karnik L, Tudor-Williams G, Kelly AM, et al
    Juvenile myelomonocytic leukemia in an infant with congenital HIV and CMV infection.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24815.
    PubMed    


  327. CROMBIE J, Davids MS
    IGHV Mutational Status Testing in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2017 Jun 7. doi: 10.1002/ajh.24808.
    PubMed     Abstract available


  328. SALEM A, Loghavi S, Tang G, Huh YO, et al
    Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Am J Hematol. 2017;92:520-528.
    PubMed     Abstract available


  329. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.
    Am J Hematol. 2017;92:E91-E93.
    PubMed    


  330. DE ROCCO D, Melazzini F, Marconi C, Pecci A, et al
    Mutations of RUNX1 in families with inherited thrombocytopenia.
    Am J Hematol. 2017;92:E86-E88.
    PubMed    


    May 2017
  331. RASHIDI A, Ali AM, Vij KR, Shanley R, et al
    Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
    Am J Hematol. 2017 May 31. doi: 10.1002/ajh.24804.
    PubMed    


  332. JABBOUR E, Daver NG, Short NJ, Huang X, et al
    Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.
    Am J Hematol. 2017 May 27. doi: 10.1002/ajh.24799.
    PubMed     Abstract available


  333. KONDO T, Nagamura-Inoue T, Tojo A, Nagamura F, et al
    Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
    Am J Hematol. 2017 May 20. doi: 10.1002/ajh.24793.
    PubMed     Abstract available


  334. ALDOSS I, Song J, Stiller T, Nguyen T, et al
    Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24783.
    PubMed     Abstract available


  335. RAGON BK, Daver N, Garcia-Manero G, Ravandi F, et al
    Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia.
    Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24782.
    PubMed     Abstract available


  336. GONCALVES MV, Rodrigues CA, Metze IGHL, Lacerda MP, et al
    Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases.
    Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24779.
    PubMed    


  337. NANAH R, McCullough K, Hogan W, Begna K, et al
    Outcome of Elderly Patients after Failure to Hypomethylating Agents Given as Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience.
    Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24780.
    PubMed     Abstract available


  338. CASTAGNETTI F, Gugliotta G, Breccia M, Iurlo A, et al
    The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Am J Hematol. 2017 May 2. doi: 10.1002/ajh.24774.
    PubMed     Abstract available



  339. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.
    Am J Hematol. 2017;92:E85.
    PubMed    


    April 2017
  340. CANAANI J, Savani BN, Labopin M, Michallet M, et al
    ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia - a report from the acute leukemia working party of the EBMT.
    Am J Hematol. 2017 Apr 25. doi: 10.1002/ajh.24771.
    PubMed     Abstract available


  341. BHATT VR, Shostrom V, Giri S, Gundabolu K, et al
    Early Mortality and Overall Survival of Acute Myeloid Leukemia Based on Facility Type.
    Am J Hematol. 2017 Apr 24. doi: 10.1002/ajh.24767.
    PubMed     Abstract available


  342. LARSEN JT, Shanafelt TD, Leis JF, LaPlant B, et al
    Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study.
    Am J Hematol. 2017 Apr 12. doi: 10.1002/ajh.24762.
    PubMed     Abstract available


  343. BAPTISTA MJ, Granada I, Morgades M, Calasanz MJ, et al
    Monosomal karyotype in chronic lymphocytic leukemia: association with clinical and biological features and potential prognostic significance.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24754.
    PubMed    


  344. REDA G, Cassin R, Fattizzo B, Giannarelli D, et al
    Chronic lymphocytic leukemia (CLL) and prognostic models: A bridge between clinical and biological markers.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24755.
    PubMed    


  345. SACHA T, Gora-Tybor J, Szarejko M, Bober G, et al
    A multicenter prospective study on efficacy and safety of imatinib generics; a report from Polish Adult Leukemia Group imatinib generics registry.
    Am J Hematol. 2017 Apr 4. doi: 10.1002/ajh.24748.
    PubMed     Abstract available


  346. YU Y, Zhang T, Wang Q, Wu D, et al
    Counting bone marrow blasts as a percentage of nonerythroid cells improves the prognostic evaluation of MDS with erythroid predominance.
    Am J Hematol. 2017;92:E55-E57.
    PubMed    


  347. PEMMARAJU N, Jain P, Medeiros LJ, Jorgenson JL, et al
    PET-positive lymphadenopathy in CLL-Not always Richter transformation.
    Am J Hematol. 2017;92:405-406.
    PubMed    


    March 2017
  348. WEINBERG OK, Gibson CJ, Blonquist TM, Neuberg D, et al
    NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO Classification.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24739.
    PubMed    


  349. CANAANI J, Labopin M, Socie G, Nihtinen A, et al
    Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24737.
    PubMed     Abstract available


  350. KANTARJIAN HM, Schuster MW, Jain N, Advani A, et al
    A Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients With Acute Myeloid Leukemia.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24736.
    PubMed     Abstract available


  351. ALFONSO A, Montalban-Bravo G, Takahashi K, Jabbour EJ, et al
    Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24735.
    PubMed     Abstract available


  352. KANDARPA M, Wu YM, Robinson D, Burke PW, et al
    Clinical Characteristics and Whole Exome/Transcriptome Sequencing of Coexisting Chronic Myeloid Leukemia and Myelofibrosis.
    Am J Hematol. 2017 Mar 23. doi: 10.1002/ajh.24728.
    PubMed     Abstract available


  353. GRIFFIN PT, Komrokji RS, Sweet K, Al Ali NH, et al
    Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
    Am J Hematol. 2017;92:232-237.
    PubMed     Abstract available


    February 2017
  354. NAKASONE H, Fuji S, Yakushijin K, Onizuka M, et al
    Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation.
    Am J Hematol. 2017;92:171-178.
    PubMed     Abstract available


  355. DINARDO CD, Luskin MR, Carroll M, Smith C, et al
    Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.
    Am J Hematol. 2017;92:E14-E15.
    PubMed    


    January 2017
  356. TEFFERI A, Barbui T
    Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2017;92:94-108.
    PubMed     Abstract available


  357. RAGON BK, Kantarjian H, Jabbour E, Ravandi F, et al
    Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
    Am J Hematol. 2017;92:7-11.
    PubMed     Abstract available


  358. JAIN P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, et al
    Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).
    Am J Hematol. 2017;92:E3-E4.
    PubMed    


  359. JAIN P, Nagarajan P, Prayag P, Benton CB, et al
    Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML.
    Am J Hematol. 2017;92:119-120.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: